histori
quinolon
began
isol
byproduct
chloroquin
synthesi
georg
yohe
lesher
colleagu
sterlingwinthrop
research
institut
renssela
new
york
compound
found
antibacteri
activ
subsequ
modifi
yield
nalidix
acid
nalidix
acid
chloroquin
share
structur
featur
essenti
antibacteri
antiparasit
activ
respect
apart
wellknown
antimalari
effect
chloroquin
exert
direct
antivir
antifung
antibacteri
effect
furthermor
chloroquin
exhibit
immunomodulatori
activ
found
revers
pglycoprotein
pgp
mediat
multidrug
resist
therebi
increas
cytotox
antineoplast
agent
antimalari
effect
chloroquin
due
accumul
acid
food
vacuol
intraerythrocyt
trophozoit
therebi
prevent
hemoglobin
degrad
inhibit
haem
polymeras
enzym
antivir
antifung
antibacteri
activ
chloroquin
phdepend
phenomenon
due
fact
chloroquin
weak
base
therefor
enter
cell
extracellular
fluid
incub
medium
acid
chloroquin
enter
cell
intercal
dna
prevent
introduct
topoisomeras
iimedi
dna
break
intercal
chloroquin
dna
protect
cell
epipodophyllotoxin
etoposid
act
topoisomeras
ii
poison
hinder
dna
cleavag
reaction
target
enzym
use
chloroquin
treatment
autoimmun
diseas
antiinflammatori
properti
may
due
inhibit
mhc
class
ii
antigen
present
inhibit
tcell
respons
may
due
direct
interact
chloroquin
cell
membran
furthermor
chloroquin
found
destabil
indirectli
lysosom
plasma
membran
result
accumul
within
lysosom
follow
increas
lysosom
volum
also
sequest
import
cell
membran
constitu
lysosom
chloroquin
found
adsorb
plasma
membran
yeast
inhibit
competit
bind
immunoglobulin
g
cell
surfac
alter
phospholipid
turnov
influenc
directli
nonspecif
membran
integr
permeabl
renal
brush
border
vesicl
mast
cell
membran
fibroblast
furthermor
chloroquin
block
inward
rectifi
potassium
channel
bound
center
cytoplasm
domain
channel
data
demonstr
congen
fluoroquinolon
ie
chloroquin
exhibit
apart
antimalari
activ
pleiotrop
action
interact
multipl
target
chloroquin
nalidix
acid
share
structur
featur
essenti
activ
surpris
recogn
late
nalidix
acid
oxolin
acid
deriv
exert
trypanocid
antitumor
activ
earli
describ
fluoroquinolon
use
treatment
bacteri
infect
exert
antibacteri
also
antiprotozo
activ
may
find
applic
antiparasit
antifung
antivir
agent
furthermor
analog
chloroquin
activ
antibacteri
activ
fluoroquinolon
phdepend
bind
directli
bacteri
dna
ie
two
molecul
intercal
highli
bent
dna
gate
dna
cleavag
domain
despit
phenotyp
molecular
homolog
chloroquin
fluoroquinolon
pharmaceut
industri
invest
financi
human
resourc
focus
research
program
applic
development
fluoroquinolon
antibacteri
pre
postmarket
studi
support
use
fluoroquinolon
oncegr
indic
studi
function
antibacteri
agent
exert
pleiotrop
antiinfect
action
never
perform
systemat
surprisingli
use
fluoroquinolon
indic
bacteri
infect
never
exploit
although
nalidix
acid
congen
chloroquin
exert
pleiotrop
action
eg
aminoglycosid
character
broad
rang
biolog
activ
multitud
antimicrobi
effect
would
unusu
review
summar
pleiotrop
phenotyp
nonantibacteri
action
fluoroquinolon
address
question
divers
effect
due
one
common
mode
action
antibacteri
activ
fluoroquinolon
ie
inhibit
essenti
bacteri
type
ii
topoisomeras
mechan
may
mediat
nonantibacteri
activ
although
complex
divers
prokaryot
eukaryot
topoisomeras
remark
littl
sequenc
homolog
amino
acid
exist
type
type
ii
topoisomeras
share
certain
structur
element
mediat
ident
function
like
dna
relax
dna
transport
bacteria
dna
virus
yeast
parasit
dna
helicas
coordin
direction
topoisomeras
activ
rna
helicas
present
eg
hepat
c
viru
hcv
directli
interact
doublestrand
dna
rna
assembl
complex
type
ii
topoisomeras
dna
topoisomeras
ubiquit
enzym
control
dna
topolog
conceiv
antibacteri
activ
quinolon
may
inhibit
growth
bacteria
clinic
relev
concentr
prokaryot
even
eukaryot
organ
well
ciprofloxacin
ofloxacin
levofloxacin
gatifloxacin
found
clinic
effect
treatment
singlestrand
rna
hcv
nonenvelop
encapsul
dna
polyomaviru
bk
five
four
patient
hcvinduc
chronic
hepat
compens
liver
cirrhosi
respect
treat
mg
ofloxacin
per
day
one
eight
week
three
patient
chronic
hepat
one
patient
compens
liver
cirrhosi
hcv
rna
decreas
least
log
titer
anoth
studi
five
patient
chronic
hcv
treat
mg
ciprofloxacin
twice
daili
bid
day
serum
hcv
rna
level
remain
larg
unchang
patient
latter
studi
indic
antihcv
efficaci
quinolon
may
limit
patient
advanc
liver
cirrhosi
ciprofloxacin
decreas
bk
peak
viral
load
hematopoiet
stem
cell
transplant
reduct
viremia
demonstr
two
month
cours
gatifloxacin
mgd
transplant
recipi
activ
bk
viru
replic
retrospect
analysi
reveal
use
either
ciprofloxacin
mg
bid
levofloxacin
mg
daili
qd
within
first
month
post
transplant
month
transplant
associ
significantli
lower
oneyear
rate
bk
viremia
recent
studi
nine
kidney
transplant
recipi
persist
bk
infect
reveal
three
month
post
ciprofloxacin
treatment
mg
bid
day
viru
load
clear
complet
three
patient
decreas
anoth
three
patient
patient
treat
antiinfect
fluoroquinolon
fluoroquinolon
inhibit
bk
viral
replic
vitro
ofloxacin
levofloxacin
inhibit
polyomaviru
bk
replic
primari
human
kidney
cell
dosedepend
manner
yield
inhibit
bk
viru
genom
replic
reduc
h
post
infect
kidney
cell
h
inocul
kidney
cell
reduct
genom
replic
protein
express
less
pronounc
dosedepend
cytostat
effect
note
infect
cell
mgl
ofloxacin
led
inhibit
cellular
dna
replic
total
metabol
activ
respect
mgl
levofloxacin
exhibit
slightli
mark
cytostat
effect
particularli
uninfect
cell
ciprofloxacin
moxifloxacin
levofloxacin
ofloxacin
gatifloxacin
norfloxacin
inhibit
bk
viru
replic
concentr
rang
mgl
ciprofloxacin
ofloxacin
levofloxacin
gatifloxacin
trovafloxacin
inhibit
viral
replic
simian
viru
anoth
member
polyomavirida
permiss
monkey
cell
well
plaqu
format
dna
replic
helicas
activ
ciprofloxacin
levofloxacin
ofloxacin
inhibit
significantli
helicas
activ
mm
wherea
trovafloxacin
inhibit
helicas
activ
recent
demonstr
norfloxacin
ofloxacin
flumequin
enrofloxacin
cinoxacin
enoxacin
fleroxacin
lomefloxacin
balofloxacin
difloxacin
inhibit
hcv
replic
particular
hepatoma
cell
line
hcv
helicas
activ
concentr
inhibit
hcv
rna
replic
rang
inhibit
helicas
activ
rang
clinic
studi
review
one
recent
report
success
treatment
kidney
retranspl
patient
ciprofloxacin
mg
bid
day
need
overal
increas
immunosuppress
due
acut
reject
suggest
fluoroquinolon
treatment
polyomaviru
bk
infect
transplant
patient
may
benefici
therefor
studi
protocol
random
control
clinic
trial
evalu
prophylact
efficaci
fluoroquinolon
design
regist
clinicaltrialsgov
levofloxacin
dose
mg
qd
administ
month
compar
placebo
anoth
clinic
studi
use
ciprofloxacin
mg
qd
month
compar
placebo
prevent
bk
infect
regist
furthermor
demonstr
ofloxacin
levofloxacin
inhibit
viral
topoisomeras
activ
vaccinia
viru
herp
simplex
viru
influenza
viru
agreement
find
report
mgl
ciprofloxacin
lomefloxacin
ofloxacin
pefloxacin
rufloxacin
inhibit
cytopath
effect
herp
simplex
viru
type
concentr
equival
cytotox
effect
quinolon
vero
cell
fluoroquinolon
inhibit
enzym
activ
viral
topoisomeraseshelicas
inhibit
vitro
human
immunodefici
viru
hiv
revers
transcriptas
well
complet
inhibit
observ
concentr
ciprofloxacin
ofloxacin
norfloxacin
respect
inhibit
rhinoviru
rv
infect
quinolon
due
inhibit
cell
function
requir
viral
replic
levofloxacin
pretreat
yet
infect
human
tracheal
epitheli
cell
reduc
mrna
level
intercellular
adhes
molecul
receptor
rv
cell
concentr
solubl
form
supernat
rv
infect
tracheal
epitheli
cell
significantli
reduc
levofloxacin
pretreat
also
decreas
number
acid
endosom
rv
rna
enter
cytoplasm
furthermor
levofloxacin
pretreat
inhibit
activ
nuclear
factor
protein
data
suggest
levofloxacin
inhibit
rv
infect
first
reduc
express
level
number
acid
endosom
second
modul
airway
inflamm
fluoroquinolon
levofloxacin
studi
context
moxifloxacin
gatifloxacin
inhibit
concentr
use
topic
applic
ophthalmolog
candida
spp
gatifloxacin
sparfloxacin
show
activ
qualit
paper
disk
diffus
test
trichophyton
rubrum
fusarium
solani
candida
albican
saccharomyc
cerevisia
ciprofloxacin
moxifloxacin
levofloxacin
trovafloxacin
sitafloxacin
enhanc
activ
antifung
agent
candida
albican
aspergillu
fumigatu
furthermor
ciprofloxacin
show
synerg
azol
histoplasma
capsulatum
coccidioid
posadasii
well
combin
amphotericin
b
exophiala
spinifera
sever
still
rare
report
clinic
microbiolog
cure
fungal
kerat
quinolon
publish
recent
five
addit
case
fungal
kerat
treat
success
topic
moxifloxacin
monotherapi
publish
caus
organ
curvularia
spp
candida
parapsilosi
paecilomyc
lilacinum
aspergillu
fumigatu
treat
moxifloxacin
one
drop
everi
halfhour
everi
hour
case
fungal
kerat
cure
topic
moxifloxacin
pathogen
elimin
data
demonstr
topic
administr
quinolon
thu
gener
high
target
site
concentr
clinic
effect
treatment
fungal
ophthalmolog
infect
topoisomeras
ii
identifi
primari
target
quinolon
yeast
antifung
activ
fluoroquinolon
test
like
mediat
enzym
dna
topoisomeras
ii
isol
candida
albican
suscept
quinolon
calf
thymu
dna
topoisomeras
ii
despit
fact
enzym
eukaryot
origin
yeast
dna
topoisomeras
ii
select
resist
quinolon
character
amino
acid
mutat
homolog
mutat
gyra
escherichia
coli
differ
yeast
mammalian
type
ii
topoisomeras
may
explain
fluoroquinolon
exhibit
antifung
activ
maintain
parallel
select
toxic
prokaryot
topoisomeras
although
antibacteri
activ
fluoroquinolon
deriv
antimalaria
agent
chloroquin
clinic
efficaci
norfloxacin
plasmodium
falciparum
discov
chanc
agent
use
treatment
typhoid
fever
indian
patient
norfloxacin
administ
nine
hospit
malaria
patient
oral
mg
norfloxacin
bid
three
day
treatment
led
disappear
splenomegali
later
anoth
patient
uncompl
malaria
treat
norfloxacin
ten
mg
bid
five
mg
bid
three
day
studi
confirm
norfloxacin
clinic
effect
treatment
falciparum
malaria
efficaci
lower
dose
suboptim
later
demonstr
norfloxacin
inferior
chloroquin
falciparum
malaria
prospect
random
trial
reveal
mean
parasit
clearanc
time
well
mean
defervesc
time
shorter
chloroquin
group
fluoroquinolon
like
ciprofloxacin
amifloxacin
enoxacin
norfloxacin
ofloxacin
pefloxacin
grepafloxacin
trovafloxacin
addit
commerci
avail
quinolon
exhibit
mark
vitro
activ
vivo
efficaci
plasmodium
spp
nalidix
acid
sever
fluoroquinolon
like
ciprofloxacin
norfloxacin
enoxacin
ofloxacin
fleroxacin
clinafloxacin
pefloxacin
sparfloxacin
exert
antitrypanosom
vitro
vivo
effect
micromolar
concentr
addit
nalidix
acid
norfloxacin
ofloxacin
moxifloxacin
gatifloxacin
lomefloxacin
fluoroquinolon
inhibit
growth
microsporidia
encephalitozoon
intestinali
vittaforma
cornea
concentr
rang
furthermor
ciprofloxacin
caus
growth
inhibit
babesia
microti
b
bigemina
b
cabal
b
equi
b
bovi
concentr
fluoroquinolon
exert
antitoxoplasma
activ
well
moxifloxacin
gatifloxacin
trovafloxacin
grepafloxacin
activ
agent
inhibit
growth
gondii
concentr
rang
mgl
ciprofloxacin
poorli
activ
inhibitori
concentr
valu
mgl
parasit
phylum
apicomplexa
ie
plasmodium
spp
toxoplasma
spp
babesia
spp
leishmania
spp
character
absenc
organel
like
mitochondria
acquir
plastid
endosymbiosi
green
alga
apicoplast
nonphotosynthet
plastid
sever
essenti
biosynthet
pathway
sequest
interact
biosynthet
function
caus
deleteri
effect
elimin
plastid
total
inhibit
function
result
delay
death
ie
parasit
grow
evad
normal
within
first
host
cell
replic
halt
immedi
invas
new
host
cell
apicoplast
harbor
circular
dna
bacteri
type
dna
gyras
ciprofloxacin
induc
cleavag
apicoplast
dna
p
falciparum
without
target
nuclear
dna
exposur
toxoplasma
gondii
ciprofloxacin
result
decreas
apicoplast
genom
copi
number
replic
although
discuss
differ
role
apicoplast
toxoplasma
plasmodium
may
exist
apicoplast
dna
gyras
isol
speci
inhibit
almost
ident
concentr
apicoplast
dna
gyras
isol
plasmodium
falciparum
inhibit
ciprofloxacin
concentr
rang
trovafloxacin
inhibit
apicoplast
dna
gyras
activ
isol
toxoplasma
gondii
plasmodium
falciparum
respect
consequ
prokaryot
type
ii
dna
topoisomeras
apicomplexan
protozoa
effect
target
fluoroquinolon
summar
previous
fluoroquinolon
activ
preclin
infect
model
quinoloneresist
bacteria
well
candida
albican
infect
furthermor
levofloxacin
activ
rv
infect
phenomena
found
directli
correl
immunomodulatori
activ
fluoroquinolon
mechan
underli
variou
immunomodulatori
effect
fluoroquinolon
includ
effect
intracellular
cyclic
phosphodiesteras
well
effect
transcript
factor
also
trigger
effect
eukaryot
equival
bacteri
so
respons
ensu
intracellular
event
fluoroquinolon
routin
prescrib
treatment
coronavirusassoci
sever
acut
respiratori
syndrom
sar
opportunist
bacteri
infect
hivposit
patient
upon
elimin
bacteri
pathogen
exclus
bacteri
pathogen
antibiot
therapi
withdrawn
howev
patient
may
benefit
immunomodulatori
activ
fluoroquinolon
effect
cours
sar
acquir
immun
defici
syndrom
aid
undetermin
although
well
document
nalidix
acid
fluoroquinolon
modul
immun
respons
modul
intracellular
signal
cascad
unknown
mechan
may
trigger
signal
transduct
demonstr
analog
chloroquin
fluoroquinolon
bind
insert
pro
eukaryot
membran
respect
therebi
alter
fluiditi
chang
membran
fluiditi
may
sens
immunocompet
cell
gene
express
may
control
accord
signal
trigger
furthermor
hypothes
fluoroquinolon
exert
direct
antiinfect
activ
due
physicochem
interact
membran
thu
make
organ
leaki
follow
cell
death
latter
aspect
never
address
systemat
fluoroquinolon
use
treatment
bacteri
infect
exert
parallel
antibacteri
action
antivir
antifung
antiparasit
action
clinic
achiev
concentr
broad
rang
antiinfect
activ
due
one
common
mode
action
ie
inhibit
type
ii
topoisomeras
thu
maintain
select
toxic
fluoroquinolon
inhibit
microbi
topoisomeras
eukaryot
topoisomeras
prokaryot
origin
low
concentr
mammalian
topoisomeras
much
higher
concentr
strong
evid
broad
rang
antiinfect
activ
translat
clinic
arena
howev
antiinfect
activ
antibacteri
activ
never
evalu
systemat
may
due
strategi
pharmaceut
industri
regulatori
author
develop
agent
basi
applic
ie
use
antibacteri
agent
therefor
antivir
antifung
activ
fluoroquinolon
far
exploit
systemat
two
control
studi
evalu
antivir
effect
fluoroquinolon
initi
recent
clinic
evalu
antifung
antiparasit
effect
justifi
would
opportun
tradit
clinic
studi
design
basi
monocaus
associ
ie
presenc
one
bacteri
speci
site
infect
indic
pathogen
consequ
antiinfect
agent
consid
effect
singl
speci
erad
focu
infect
howev
infect
may
polymicrobi
chronic
ill
patient
may
suffer
opportunist
infect
hivposit
patient
repres
extrem
exampl
acquisit
opportunist
infect
caus
parallel
virus
bacteria
andor
parasit
patient
could
theori
benefit
treatment
agent
exert
broad
rang
antiinfect
activ
multifactori
analysi
outcom
infecti
diseas
would
necessari
correspond
outcom
measur
quantifi
link
pharmacokinet
overal
clinic
efficaci
summari
base
one
common
mode
action
fluoroquinolon
commerci
avail
antibacteri
agent
activ
virus
fungi
parasit
class
agent
probabl
repres
broadspectrum
antiinfect
true
sens
